Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG

Rhea-AI Summary

Ernexa Therapeutics (Nasdaq: ERNA) appointed Dr. Ira S. Winer, M.D., Ph.D., FACOG, to its Scientific and Medical Advisory Board on December 2, 2025. Dr. Winer is a gynecologic oncologist and translational scientist who serves as Professor (Clinician Educator) at Wayne State University School of Medicine and practices at Barbara Ann Karmanos Cancer Institute.

The appointment strengthens clinical and translational expertise as Ernexa advances its iMSC cell therapy platform and lead program ERNA-101 toward first-in-human trials, with a focus on ovarian cancer and expansion into inflammatory and autoimmune indications.

News Market Reaction – ERNA

-4.00%

4 alerts

-4.00% Session close to close

+5.8% Peak Tracked

-3.8% Trough Tracked

$9.42M Market Cap

1.1x Rel. Volume

In the Dec 2 session, ERNA declined 4.00%, reflecting a moderate negative market reaction. Argus tracked a peak move of +5.8% during that session. Argus tracked a trough of -3.8% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement adds gynecologic oncology and immunotherapy expertise to ERNA’s advisory ranks as ...

Analysis

This announcement adds gynecologic oncology and immunotherapy expertise to ERNA’s advisory ranks as the company advances its iMSC platform and lead asset ERNA-101 toward first-in-human trials. Recent filings showed improved losses but a modest cash balance of $3.05M and an accumulated deficit of $242.9M, with substantial doubt disclosed about going concern. Key metrics to watch include progress on IND-enabling work, trial initiation timing, and future financing or partnership updates.

Key Figures

Operating loss decline: 44% Q3 2025 net loss: $1.24M Year-to-date net loss: $12.58M +5 more

8 metrics

Operating loss decline 44% Nine months ended Sept 30, 2025 vs prior year

Q3 2025 net loss $1.24M Quarter ended Sept 30, 2025 (vs $26.60M prior year)

Year-to-date net loss $12.58M Nine months ended Sept 30, 2025 (vs $38.78M in 2024)

Cash balance $3.05M As of Sept 30, 2025; company flagged substantial doubt as going concern

Accumulated deficit $242.9M As of mid-2025 per 10-Q

Preclinical survival advantage 58.2% ERNA-101 preclinical data in ovarian cancer model

Cytokine levels ≈20-fold higher IL-7/IL-15-secreting iMSCs vs prior engineered T-cell approaches

52-week range $1.09–$14.40 ERNA share price over last 52 weeks

Historical Context

5 past events · Latest: Dec 08 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 08	Preclinical data	Positive	-1.5%	New ERNA-101 preclinical data showing immune activation and survival benefit.
Dec 03	Conference presentation	Positive	-4.2%	ASH oral presentation announcement for iMSC platform and ERNA-101 data.
Dec 02	Advisory appointment	Positive	-4.0%	Appointment of gynecologic oncologist to strengthen clinical advisory depth.
Nov 11	Conference participation	Positive	-5.4%	Cell 2025 presentations on iMSC platform strategy and trial design plans.
Nov 10	Operational update	Positive	-4.6%	Quarterly update with 44% operating loss decline and ERNA-101 advancement plans.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Across recent positive program, presentation, and management updates, ERNA has repeatedly traded down in the following 24 hours, suggesting a pattern of bearish reactions to ostensibly constructive news.

Recent Company History

This announcement adds to a series of 2025 updates focused on building ERNA’s iMSC platform and advancing lead program ERNA-101. Recent news included preclinical efficacy data and an ASH oral presentation, plus a quarterly update highlighting a 44% year-over-year operating loss decline and IND timing toward H2 2026 first-in-human trials. Despite these seemingly positive milestones, each of the last five news events saw negative 24-hour price reactions, framing today’s management-focused update within a broader trend of selling into news.

Key Terms

induced mesenchymal stem cells (iMSC), induced pluripotent stem cells (iPSCs), allogeneic, immunotherapy, +1 more

5 terms

induced mesenchymal stem cells (iMSC) medical

"advances its proprietary induced mesenchymal stem cells (iMSC) platform"

Induced mesenchymal stem cells (iMSCs) are ordinary adult cells that scientists convert to behave like mesenchymal stem cells, which can multiply and become connective tissues such as bone, cartilage or fat and support healing. Investors watch iMSC programs because successful therapies could treat degenerative conditions and create new revenue streams, but they also carry clinical, manufacturing and regulatory risks similar to other advanced cell therapies — like building a custom spare-parts factory for the body.

induced pluripotent stem cells (iPSCs) medical

"engineering induced pluripotent stem cells (iPSCs) into allogeneic iMSCs"

Cells that have been reprogrammed from adult tissue to behave like embryonic stem cells, capable of turning into many different cell types much like resetting a specialized tool back to a blank one that can be reshaped. Investors care because these cells enable development of new medicines, disease models and testing platforms that can lower drug-development costs and open large markets, but they also carry long timelines, scientific hurdles and regulatory risk.

allogeneic medical

"into allogeneic iMSCs as off-the-shelf therapies"

Allogeneic describes a process or material involving different individuals of the same species, such as cells, tissues, or organs donated from one person to another. It is important to investors because products or treatments based on allogeneic sources can enable scalable, off-the-shelf solutions, potentially reducing costs and increasing accessibility in healthcare and biotech industries.

immunotherapy medical

"expertise in women’s oncology, immunotherapy, and early-phase clinical development"

Treatment that uses or enhances the body’s immune system to detect and fight disease, most often cancers or chronic infections; think of it as training or arming the body’s own soldiers to find and destroy targets. It matters to investors because successful immunotherapies can lead to high-value drug approvals, recurring revenue from long-term treatments, and changes in competitive dynamics, while failures or safety issues in clinical trials can materially affect company valuations.

translational research medical

"grounding his approach to gynecologic cancers in scientific innovation and translational research"

Translational research turns laboratory discoveries into tests, treatments, or medical products for people, acting as the bridge between basic science and practical use. Like converting a prototype into a store-ready product, it shows whether promising biology can become a safe, regulated, and sellable therapy, diagnostic, or device. For investors, clear translational progress reduces technical and regulatory uncertainty, creates milestone-driven value, and signals when commercial returns might be possible.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Appointment reinforces clinical and translational depth as Ernexa advances its best-in-class iMSC cell therapy platform into first-in-human trials

CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the appointment of Dr. Ira S. Winer, M.D., Ph.D., FACOG, to its Scientific and Medical Advisory Board.

Dr. Winer is a nationally recognized gynecologic oncologist and translational scientist. His expertise in women’s oncology, immunotherapy, and early-phase clinical development further strengthens Ernexa’s capabilities as it advances its proprietary induced mesenchymal stem cells (iMSC) platform and lead program, ERNA-101, toward key milestones, including first-in-human trials.

“We are delighted to welcome Dr. Winer to our Advisory Board,” said Sanjeev Luther, President and CEO of Ernexa Therapeutics. “His deep clinical and translational experience in women’s oncology directly supports our mission to advance treatments for advanced cancer and autoimmune disease. As we move ERNA-101 forward in ovarian cancer and expand our pipeline into inflammatory and autoimmune indications, Dr. Winer’s strategic guidance will help us translate innovation into meaningful clinical outcomes.”

Dr. Winer added, “I am honored to join the Advisory Board of Ernexa Therapeutics at such a pivotal moment. Ernexa’s focus on engineering induced pluripotent stem cells (iPSCs) into allogeneic iMSCs as off-the-shelf therapies reflects both scientific innovation and a deep commitment to patients. I look forward to contributing my experience in translational and clinical science to help guide Ernexa’s path from promising innovation to meaningful patient outcomes.”

Dr. Winer serves as a Professor (Clinician Educator) in the Department of Oncology at Wayne State University School of Medicine, and as a distinguished gynecologic oncologist and surgical oncologist at the Barbara Ann Karmanos Cancer Institute. At Karmanos, Dr. Winer is widely recognized for his surgical skill and leadership in early-phase clinical trials, offering patients access to cutting-edge therapies in ovarian, endometrial, cervical, fallopian tube, and vulvar cancers.      

In addition to his clinical practice, he holds a Ph.D. in cellular and molecular biology, grounding his approach to gynecologic cancers in scientific innovation and translational research. Widely published and an active member of professional societies, Dr. Winer’s work focuses on ovarian, uterine, cervical, and vulvar cancers, with a particular emphasis on immunotherapy, molecularly targeted treatments, and translational research that bridges laboratory science and patient care.

About Ernexa Therapeutics

Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.

ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-201 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer.

For more information, visit www.ernexatx.com.

Media Contact
Sharon Golubchik
RAYNZ
sharon@raynzhealth.com

Investor Contact
Jenene Thomas
JTC Team, LLC
(908) 824-0775
ENRA@jtcir.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/de652864-7d39-4b89-873f-72a4b65d76be

FAQ

Who was appointed to Ernexa Therapeutics' Scientific and Medical Advisory Board on December 2, 2025 (ERNA)?

Ernexa appointed Dr. Ira S. Winer, M.D., Ph.D., FACOG to its Scientific and Medical Advisory Board on December 2, 2025.

What experience does Dr. Ira Winer bring to Ernexa (ERNA) for ERNA-101 trials?

Dr. Winer brings experience in women's oncology, immunotherapy, and early-phase clinical development, and holds a Ph.D. in cellular and molecular biology.

How does Dr. Winer's appointment affect Ernexa's iMSC program and ERNA-101 (ERNA)?

The appointment bolsters clinical and translational guidance as Ernexa advances its iMSC platform and prepares ERNA-101 for first-in-human trials.

Which indications will Ernexa focus on for ERNA-101 after adding Dr. Winer to the advisory board (ERNA)?

Ernexa intends to move ERNA-101 forward in ovarian cancer and expand into inflammatory and autoimmune indications.

Where does Dr. Ira Winer practice and teach, as noted in the Ernexa announcement (ERNA)?

Dr. Winer is a Professor (Clinician Educator) at Wayne State University School of Medicine and a gynecologic oncologist at Barbara Ann Karmanos Cancer Institute.

Does the Ernexa announcement (ERNA) specify trial timing or financial guidance for ERNA-101?

No; the announcement notes advancement toward first-in-human trials but does not provide specific timelines or financial guidance.